Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

CuraTeQ’s Biosimilar Trastuzumab Receives Positive CHMP Opinion in EU

Apr 25, 2025

At its April meeting, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Aurobindo Pharma’s subsidiary CuraTeQ’s Dazublys® (150 mg powder for concentrate for solution for infusion), biosimilar to Roche’s Herceptin® (trastuzumab).  The biosimilar is indicated for HER2-positive metastatic and early breast cancers.  According to Aurobindo, European Commission approval is expected in July 2025.

The first trastuzumab biosimilar was approved in the EU in November 2017 and in the US in December 2017.